Worked with a large, global, pharmaceutical corporation discovering, developing, and marketing a large portfolio of human and animal therapeutic products. In order to allow increased focus on its oncology, vaccines, hospital medicine and animal health segments, the company will spin off products from its women’s health and biosimilars businesses, along with certain legacy brands, into a new independent and publicly traded company. PPT Consulting provided a divestiture strategy and project portfolio to enable the stand-up and separation of this new company.


  • Lead Divestiture Strategy development for the strategy team
  • Provide Project Management support to stand up new company as operating as a Company-within-Company
  • Provide Project Management support for ultimate separation of both companies
  • Support OPEX refinements to on-going operations (post-change)


  • Employed Reflection Methodology to decompose required Capabilities, facilitating definitions of requirements for sourcing, facilities, systems, and data
  • Validated Capabilities through workshops and global stakeholder communications, assuring quality leading into project planning
  • Developed initial project plans for soliciting, developing, and executing contracts for transition services enabling stand-up of Company-in-Company operations
  • Developed initial project plans for IT, data, and process workstreams, assuring integration throughout functional plans
  • Developed initial project plans for functional areas of Global Regulatory Affairs, Clinical Safety, Clinical Trial Operations, and Quality